Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
INACTIVATED NEWCASTLE DISEASE VIRUS STRAIN LA SOTA
Zoetis Ireland Limited
QI01EA01
INACTIVATED NEWCASTLE DISEASE VIRUS STRAIN LA SOTA
Suspension for Injection
POM (E): Prescription Only Exempt as defined in relevant national legislation
Avian
pigeon paramyxovirus
Immunological - Inactivated vaccine
Authorised
2014-11-24
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Colombovac PMV 2 QUALITATIVE AND QUANTITATIVE COMPOSITION PER 0.2 ML DOSE ACTIVE SUBSTANCE: Inactivated Newcastle Disease Virus, strain La Sota at least 19.9 AU* * AU: Antigen Unit ADJUVANT(S): Carbomer 934 P 1 mg EXCIPIENT(S): Thiomersal 20 µg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Suspension for injection 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigeons. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For active immunisation of pigeons to reduce mortality and clinical signs due to paramyxovirus type 1 infection. Onset of immunity one month after inoculation. Duration of immunity12 months. 4.3 CONTRAINDICATIONS Do not use in unhealthy pigeons. Do not vaccinate during the last 2 weeks prior to mating. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Not for intramuscular injection: Intramuscular injection causes severe adverse reactions. Maternally-derived antibody (MDA) can interfere with the development of active immunity. Where it is likely that recent field infection or vaccination of the parent flock has stimulated a high antibody titre and consequently a high level of MDA, the timing of the vaccination programme should be planned accordingly. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _1_ _9_ _/_ _0_ _1_ _/_ _2_ _0_ _1_ _7_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _3_ _5_ _0_ _1_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECI Lesen Sie das vollständige Dokument